

08/24/2006

10:53

TAKEDA → USPTO CENTRL FX

RECEIVED  
CENTRAL FAX CENTER

NO. 912 0002

AUG 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent No. 6,034,239  
Issued: Mar. 7, 2000  
To: Shigenori OHKAWA et. al.  
For: Tricyclic Compounds, Their Production and  
Use  
From: Serial No. 08/812,168  
Filed: Mar. 6, 1997

MAIL STOP: PATENT EXTENSION

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Via Facsimile to Central Fax  
1-571-273-8300

Sir:

PETITION TO EXPUNGE CERTAIN PROPRIETARY INFORMATION FROM  
APPLICATION FOR EXTENSION OF PATENT TERM  
OF UNITED STATES PATENT NO. 6,034,239 UNDER 37 C.F.R. §1.59

Your applicant, TAKEDA PHARMACEUTICAL COMPANY LTD. ("TAKEDA"), petitions to have certain Proprietary Confidential Information Expunged from the Application File pursuant to 37 C.F.R. §1.59.

This petition is being timely filed before the issuance of a certificate of patent term extension.

Applicants request that parts of Exhibit C, specifically pages 1, 2, 3, 4 and 6 – 38 (inclusive) be Expunged from the Patent Term Extension Application File.

Each page is clearly identified as containing proprietary confidential information of Takeda. This information has not been otherwise made public.

08/24/2006

10:53

TAKEDA → USPTO CENTRL FX

NO. 912 003

Public release of this information would be irreparably detrimental to Takeda.

Applicants herewith authorize the Commissioner to charge the appropriate fees under 37 C.F.R. §1.17 for the filing of this petition, and any other required charges, to the Applicant's USPTO deposit account No. 500 799.

Respectfully submitted,




Dated: August 24, 2006

(847)383-3372  
(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60699 USA

<b>CERTIFICATE OF FACSIMILE</b>
<b>TRANSMISSION UNDER 37 CFR 1.8</b>
The undersigned hereby certifies that this paper(s) is/are being transmitted via facsimile to the Commissioner for Patents, Washington, D.C. 20231 on this date Aug 24 2006, to the Central Fax Facsimile Number 1-703-273-8500.

Mark Chao, Ph.D., Reg. No. 37,293

08/24/2006

10:53

TAKEDA → USPTO CENTRL FX

RECEIVED  
CENTRAL FAX CENTER

NO. 912

D001

AUG 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent No. 6,034,239  
Issued: Mar. 7, 2000  
To: Shigenori OHKAWA et. al.  
For: Tricyclic Compounds, Their Production  
and Use  
From: Serial No. 08/812,168  
Filed: Mar. 6, 1997

MAIL STOP: PATENT EXTENSION

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450  
Sir:

Via Facsimile to Central Fax  
1-571-273-8300

3 Pages


TRANSMITTAL LETTER

1. Enclosed is Request to Expunge certain Proprietary Confidential Information from the Patent Term Extension Application File under 37 CFR §1.59
2. The Commissioner is authorized to charge the appropriate prescribed fees of \$200.00 (37 CFR 1.17(g)), and any other required fees, or to credit any overpayments to Applicant's USPTO Deposit Account No. 500 799 (Takeda Pharmaceutical Company Inc.).

Respectfully submitted,

Dated: August 24, 2006

(847)383-3372  
(847)383-3391

  
Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 6069 USA